Zhongchao Inc. Reports 41% Revenue Drop and Executive Turnover Amid Healthcare Education Challenges

Historical Financial Performance: Key Metrics and Revenue Trends

Zhongchao Inc.’s financial performance over the three-year period ending FY2025 highlights significant top-line contraction amidst ongoing profitability challenges. Total consolidated revenues decreased approximately 28.3% year-over-year from $15.9 million in 2024 to $11.4 million in 2025 [F1]. Comparing FY2025 to FY2023 reveals a near 41% revenue decline from $19.4 million. This decline was primarily driven by product revenue falling sharply from over $9 million in 2023 to under $700 thousand by end-2025 — reflecting the company's exit from patented drug sales following the cessation of Xinjiang Pharmaceutical operations mid-2025 [S1]. Service revenues also contracted but less steeply.

Gross profit remained positive at roughly $5.1 million in FY2025 but declined from prior years as reductions in cost of revenues lagged sales decreases. Operating income worsened substantially to a loss of $6.2 million for FY2025 — markedly deeper compared to a modest loss of $0.34 million recorded in FY2024 [F1]. Net income followed a similar pattern, with a loss around $6.3 million last fiscal year, representing an approximate ninefold increase versus the prior year.

Notably, operating cash flow returned to positive territory at approximately $845 thousand in FY2025 after two years of negative cash generation, indicating tighter working capital management despite persistent net losses. The company maintained strong liquidity with current assets exceeding current liabilities by a wide margin, resulting in an end-2025 current ratio above 11x — underscoring short-term financial flexibility during longer-term earnings pressures.

Historical performance (annual)

Source: SEC companyfacts cache [F1].

Capital returns and efficiency (annual)

Source: SEC companyfacts cache [F1].

Source: Audited consolidated financial statements for fiscal years ending December 31 [F1]

Business Model and Market Position: MDMOOC Platform and VIE Structure

Zhongchao functions as a Cayman Islands holding company that consolidates its PRC operating subsidiaries through Variable Interest Entity (VIE) contractual arrangements due to foreign ownership restrictions applicable in China [S1]. Its principal PRC operating entity is Zhongchao Medical Technology (Shanghai) Co., Ltd., supported by seven subsidiaries across key Chinese cities.

Central to Zhongchao's offerings is MDMOOC — an integrated platform providing online and offline medical education targeting healthcare professionals. Its curriculum includes clinical training modules, continuing education courses accredited for license renewal credits, interactive case studies for applied learning, academic conferences aligned with professional society standards, and accessible multimedia healthcare content distributed via mobile apps and social media channels like WeChat subscription accounts [S1].

The platform also incorporates patient management systems focusing on oncology and rare diseases that support healthcare provider-patient engagement and facilitate patient-aid programs providing access to subsidized or free drugs for qualified patients [S1].

This multi-dimensional approach combining comprehensive educational resources with patient support initiatives constitutes Zhongchao's competitive advantage. Partnerships with pharmaceutical companies further enhance content credibility and customization opportunities.

However, the reliance on VIE contractual frameworks introduces regulatory risk stemming from evolving PRC cybersecurity laws and foreign investment policies that may impact operational continuity or investor protections since equity interests are not directly held in PRC entities [S1].

Growth Drivers and Challenges

Zhongchao's historical growth has been driven by increasing demand for standardized professional medical education aligned with China's expanding healthcare workforce requirements for continuing education certification. Its extensive content library combined with user-friendly digital interfaces facilitated gradual penetration into domestic healthcare e-learning markets.

Expansion was augmented by scaling patient management platforms addressing complex disease areas such as oncology and rare diseases — creating additional monetization beyond pure education services [S1].

Nevertheless, growing competition from hospital-based training programs supported by larger incumbents or government-affiliated organizations has pressured pricing power and client retention rates. The normalization of virtual healthcare adoption post-COVID has moderated user base growth industry-wide.

Most critically are regulatory uncertainties associated with the VIE structure itself; ongoing scrutiny under PRC regulations could materially disrupt Zhongchao’s operational licenses or U.S.-based reporting status [S1]. These factors remain key constraints on sustainable growth alongside macroeconomic headwinds affecting discretionary spending on external medical education.

Recent Leadership Changes and Strategic Adjustments

In March 2026, Zhongchao announced resignations of three senior officers: Chief Medical Officer Xuejun Chen; Chief Sales Officer Baoqian Tian; and Chief Operating Officer Shuang Wu as part of strategic realignment efforts aimed at refining business focus rather than arising from internal disputes [S2].

This executive turnover reflects management's response to consecutive negative earnings periods by realigning leadership roles tied closely to product development, sales execution, and operations during a restructuring phase.

Capital Structure, Liquidity Profile, and Returns Analysis

At fiscal year-end 2025 Zhongchao held cash and equivalents totaling approximately $8.1 million alongside current assets near $17 million against current liabilities below $1.53 million — translating into a robust current ratio exceeding 11x [F1]. This liquidity position supports near-term obligations despite ongoing operating losses.

Return metrics reveal stress: approximate return on equity stands near negative -33.9%, reflecting net losses relative to shareholder equity around $18.6 million as of end-2025 [F1]. No dividends or share repurchases have been reported.

Operating cash flow improved significantly returning positive at about $845 thousand last fiscal year after prior negative years — indicating enhanced internal liquidity management despite loss-making operations [F1]. Free cash flow remains negative when considering capital expenditures though these investments were not disclosed explicitly.

Financial Reporting Controls and Risk Management Initiatives

The FY2025 annual report discloses material weaknesses in internal control over financial reporting related primarily to insufficient monitoring mechanisms such as absence of dedicated internal audit departments overseeing risk management processes [S1]. Additionally, limited US GAAP expertise within accounting functions impacted timely accurate reporting.

Management has engaged external consultants experienced with SEC compliance and increased US GAAP training efforts involving senior finance personnel including the CFO [S1]. Plans include establishing formal internal audit functions aimed at strengthening governance integrity.

These disclosures highlight execution risks typical for smaller-cap Chinese ADRs employing VIE structures amid complex cross-jurisdictional accounting requirements.

Outlook and Key Milestones Ahead

With no explicit forward guidance provided by management post-FY2025 filings, investors should monitor execution progress following recent leadership changes alongside regulatory developments affecting VIE legitimacy or broader China internet sector policies [S2][S3].

Resolution of Nasdaq minimum bid price compliance issues earlier this year removes immediate delisting threats but underlying fundamental challenges persist [S3].

Future quarterly disclosures will be critical for signs of revenue stabilization or margin improvement particularly within service segments as product segment retrenchment appears largely complete [F1][S1]. Regulatory announcements regarding foreign investment laws impacting VIE contracts remain pivotal for structural reconfiguration prospects.

This analysis is based solely on publicly available SEC filings through April 8th, 2026 without extrapolation beyond reported facts or investment recommendations.

Disclaimer: This is research-only, informational analysis and not investment advice. It may include AI-generated interpretation and general industry context. Always verify important details using primary sources.